Introduction Dysfunction of the immune system is a hallmark of cancer. Through increased
understanding of the complex interactions between immunity and cancer, immunotherapy …

Targeting inhibitory immune checkpoint molecules has dramatically changed treatment
paradigms in medical oncology. Understanding the best strategies to unleash a pre-existing …

Cancer immunotherapy has produced impressive clinical results in recent years. Despite the
success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 …

T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been
reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 …

T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression has been
a trending topic in recent years due to its differential expression in a wide range of …

Patients with malignant tumor treated with immunotherapy have received significant clinical
benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T …

Immunotherapy is being increasingly recognized as a key therapeutic modality to treat
cancer and represents one of the most exciting treatments for the disease. Fighting cancer …

T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both
mice and humans has been shown to possess various functions in a context-dependent …

T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …